As of November 6, 2026, Estrella Immunopharma, Inc. has Schedule 13D or 13G filings on record, none whose latest reports a stake of 5% or more. 2 filings are on record since May 15, 2026 (Schedule 13G/A, August 14, 2026).
Sell to companies like Estrella Immunopharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Estrella Immunopharma, Inc. has 2 Schedule 13D or 13G filings on record since 2026-05-15. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Armistice Capital, LLC | 4.99% | 2,051,409 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
Holding shares or following this stake? See who's behind Estrella Immunopharma, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Estrella Immunopharma, Inc. and the records around it.
Estrella Immunopharma, Inc. elsewhere on the record
- Leadership changes Oct 2026
- Who owns it
Companies that share a holder
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch Estrella Immunopharma, Inc.
Get an email when Estrella Immunopharma, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Estrella Immunopharma, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Estrella Immunopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Estrella Immunopharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 0 | 2,051,409 | 0 | 2,051,409 | SCHEDULE 13G/A, 2026-08-14 |
| Steven Boyd | 0 | 2,051,409 | 0 | 2,051,409 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Estrella Immunopharma, Inc. by CUSIP 297584104 and gives its principal executive office as 5858 Horton Street, Suite 370, Emeryville, CA 94608 (SCHEDULE 13G/A, 2026-08-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-05-15 | Armistice Capital, LLC | 9.99% | SCHEDULE 13G |
| 2026-08-14 | Armistice Capital, LLC | 4.99% | SCHEDULE 13G/A |
Also on the record for Estrella Immunopharma, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 29, 2026 | Leadership change: Cynthia Pussinen appointed, Chief Executive Officer | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Estrella Immunopharma, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.